Pyrimidine compounds as JAK kinase inhibitors
US10028960B2 · kind B2 · utility
16Cited by
9References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2017 |
| Grant date | Jul 24, 2018 |
| Priority date | — |
| Expiry date | Apr 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.